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year saved, $39 per QALY and $37 per DALY averted. CONCLUSIONS: For pregnant,
HIV-1 infected women presenting at delivery and not requiring antiretrovirals for
their own health, infant NVP throughout breastfeeding is likely to be considered
cost-effective. For those presenting antenatally, antenatal ZDV followed by infant
NVP throughout breastfeeding (WHO Option A) is likely to be considered cost-
effective.
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OBJECTIVES: To provide pharmacoeconomic evaluation of diagnostics of tubercu-
losis infection (TI) with Allergen tuberculosis recombinant (CFP10-ESAT6) and Al-
lergen tuberculosis purified liquid in the standard dilution for intradermal use (PPD
RT 23 SSI). METHODS: The cost-effectiveness analysis. In the study direct costs
included cost of TI diagnostics, cost of the additionally surveys, cost of observation
in the clinic and cost of treatment of TI patients. RESULTS: The efficacy of TI
diagnostics was evaluated. The frequency of diagnostics of active tuberculosis has
been evaluated on the data of the TI diagnostics in children and adolescents in
Moscow and Samara region. The proportion of patients with active tuberculosis
were 0.31%, 0.006% and 0.04% for CFP10-ESAT6, PPD RT 23 SSI and a combined
scheme of diagnostics (simulate situation when both drugs use), respectively. Di-
rect costs for TI diagnostics, surveillance and treatment of TI were calculated.
Direct costs amounted to 380.36 RUB (9.17 EUR), 218.18 RUB (5.26 EUR) and 220.46
RUB (5.31 EUR) for CFP10-ESAT6, PPD RT 23 SSI and combination scheme, on one
patient, respectively. Finally, total direct costs for the diagnostics one patient with
active tuberculosis were 122.687 RUB (2.956 EUR), 3.646.833 RUB (87.875 EUR) and
551.150 RUB (13.281 EUR), for the estimated diagnostic schemes, respectively.
CONCLUSIONS: The pharmacoeconomic study results shows, that CFP10-ESAT6 is
dominant technology from “cost-effectiveness” analysis perspective.
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OBJECTIVES: To highlight the different results obtained when conducting an eco-
nomic evaluation of RPV using response rates other than those in the SmPC.
METHODS: We considered the overall response rate of Rilpivirine (RPV) clinical
trials, and the response rates in the indicated population based on its SmPC (pa-
tients with baseline viral load  100.000 copies/ml). Efficacy was defined as the
percentage of patients having viral load  50 copies/ml at week 48 per intention-
to-treat analysis. The analysis perspective is that of the Spanish NHS, considering
in our model only the cost of the antiviral drug. Time horizon is 48 weeks and costs
are ex-factory prices (2012). Since the reimbursed price of RPV has not being ap-
proved in Spain yet, our base case assumes the hypothesis anticipated by some
Spanish HTAs that RPV could be priced as parity to the SoC, Efavirenz (EFV). Four
scenarios were performed: price parity, 2.5%, 5% and 7.5% premium price over
EFV.RESULTS: In the price parity scenario, depending on the response rate applied,
the cost per responder of RPV ranges from 3.575€ (SmPC efficacy rates) to 3.839€
(overall efficacy rates). It is estimated that HIV-1 incidence in Spain is around 2,600
new patients/year, 70% of whom would have baseline VL  100.000 copies/ml. In
the price parity scenario, since the difference in efficacy rates is 6.6% (1.6%; 11.5%)
IC 95% RPV vs EFV, initiating the treatment with RPV instead of EFV would allow to
successfully treat 120 patients more than with EFV.CONCLUSIONS: Economic eval-
uation should be conducted using response rates associated to the approved prod-
uct label to get the most accurate measure of true value. When doing so, our model
demonstrates that RPV would be more cost-effective than EFV in naïve patients
with baseline VL  100.000 copies/ml in the four scenarios analyzed.
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OBJECTIVES: Hepatitis C is an infection that when left untreated or unsuccessfully
treated, progresses into Advanced Liver Disease (ALD) associated with a high clin-
ical, humanistic and economic burden. Due to limited economic resources, health
care providers may have to choose whether to treat F2 patients with PR alone vs.
Telaprevir plus PR (TPR). This publication aims to demonstrate the clinical and
economic value of treating naïve F2 patients with TPR, a triple based regimen
compared to PR alone. METHODS: A post-hoc analysis of the phase III ADVANCE
was conducted and NNT were calculated. Cost-effectiveness of TPR vs. PR in F2
patients was determined based on a UK economic model. A cost per cure (SVR)
model analyzed the number of cured patients with TPR vs PR and number of pa-
tients treated but not cured. RESULTS: NNT in F2 patients was estimated to be 3.3.
In previously untreated F2 fibrosis patients, TPR was associated with higher costs
and improved outcomes compared to PR with an Incremental Cost Effectiveness
Ratio (ICER) of £ 9,930/ QALY. Treating 100 F2 patients with TPR results in 79 cured
patients compared with only 49 cured patients with PR. In order to achieve cure in 50
patients, 13 patients would be treated but not cured with TPR compared to 52 treated but
not cured with PR alone. With a million £ investment with TPR only 7 patients are not
cured compared to 53 patients with PR alone. CONCLUSIONS: TPR provides clinical
and economic value for F2 untreated patients. It is clinically superior treatment
versus PR, is a cost-effective treatment option and within a fixed budget choosing
TPR instead of PR results in more patients cured and in less treatment failures.
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OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. Pediatric high-risk population (PHR) (like sickle cell disease, HIV infected or
those receiving immunosuppressive medications) are 30-100 times more likely to
develop IPD compared to healthy children. This study aims to perform cost-effec-
tiveness analysis of 13-valent pneumococcal vaccine (PCV13) in PHR, from a public
payer perspective in Brazil. METHODS: A decision tree-model was developed to
simulate IPD outcomes in PHR after vaccination with PCV13 versus PCV10 and
non-vaccination and their associated direct costs in a 10-year time horizon. Despite
comparison with PCV10, this indication is off-label in Brazil and no studies are
available to this population segment. Effectiveness parameters are avoided cases
of IPD, hospitalized and non-hospitalized pneumonia. Direct medical costs in-
cluded hospital days, medical personnel time, outpatient visits, diagnostic tests
and medications. Clinical data and costs were extracted from literature, presented
in 2012 USD. Probabilistic sensitivity analyses were performed trough Monte Carlo
Simulation second-order approach. RESULTS: For a 611,737 patients cohort, PCV13
avoided [1,626; 1,851] IPD, [1,996; 92,805] hospitalized pneumonia, [1,585; 73,700]
non-hospitalized pneumonia, and [570; 649] IPD deaths, versus [PCV10; non-vacci-
nation]. Projected treatment costs for PCV13 versus PCV10 were 703,326,000USD,
and 707,410,000USD, respectively. For PCV13 versus non-vaccination projected
treatment costs was 367,000,000USD versus 705,000,000USD, respectively. In cost-
effectiveness analysis, PCV13 was cost-saving in all comparisons. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant regard-
ing life years gained than PCV10 vaccination and non-vaccination strategy.
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OBJECTIVES: To estimate the cost per sustained virological response (SVR) in ge-
notype 1 (G1) hepatitis C (HCV) patients according to previous treatment response
and METAVIR groups in Brazil. METHODS: SVR and extended rapid virological
response (eRVR) rates were from the respective phase III clinical trials of telaprevir
(ADVANCE and REALIZE) and boceprevir (SPRINT-2 and RESPOND-2) for treatment
naive patients, METAVIR F0-F3 naive patients, and treatment experienced patients
(relapsers, partial responders and null responders). When SVR and eRVR rates were
not available for a patient subgroup these were assumed to be the same as the
global patient population. Brazilian treatment costs were based on the eRVR rates
and calculated based on the prices for telaprevir and boceprevir recently published
by the HTA body CONITEC. Treatment costs for pegylated interferon and ribavirin
were calculated from the reimbursed price published in the official website:
www.comprasnet.gov.br. RESULTS: Telaprevir has the lowest cost-SVR for all pa-
tients in the analysis compared to boceprevir. In treatment naive patients, telapre-
vir has a cost-SVR of R$ 64.513 compared to boceprevir with R$ 72.275. In METAVIR
scale of F0-F3 treatment naive patients, telaprevir has a lower cost-SVR of R$
64.196, while the cost-SVR for boceprevir remains 12% higher (R$ 72.275). The low-
est cost-SVR was observed for the prior relapse patients treated with telaprevir, R$
51.283/SVR, compared to boceprevir with R$ 58.736/SVR. Boceprevir has the highest
cost-SVR at R$ 90.658 compared to R$68.144 with telaprevir for patients with a
previous partial response. For prior null-responders, telaprevir is the only option
since as these patients were not studied with boceprevir. CONCLUSIONS: Telapre-
vir has the lowest cost-SVR compared to boceprevir for the treatment of hepatitis C
G1 patients in Brazil regardless of baseline disease severity and prior treatment
response.
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OBJECTIVES: To assess the cost-effectiveness of amoxicillin clavunate compared
to amoxicillin at primary care level in Turkey for community acquired pneumonia,
acute rhinosinusitis, tonsillopharyngitis, and acute otitis media. METHODS: As
proposed by the guidelines for the treatment of diseases costs have been deter-
mined through applying cost of illness methodology. The agents have been calcu-
lated by evaluating all brands and forms over continuous doses. The perspective of
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the reimbursement institutions in Turkey has been reflected upon the costs. As a
value of effectiveness, the rate of completing the treatment has been chosen. The
success rate of completing the treatment determined as 2 doses and 3 doses per
day has been gathered from the literature. The completion level of the treatment
for 2 doses per day is 68% and for the agents used for 3 doses, it is 50%. RESULTS: In
terms of incremental cost per additional completing doses, amoxicillin clavulanate
is cost saving versus amoxicillin group for the treatment of community acquired
pneumonia (-113.43 TL), acute rhinosinusitis (-70.73 TL), acute otitis media (-70.73
TL), tonsillopharyngitis (-52.06 TL). CONCLUSIONS: According to the results de-
rived from the comparison between the costs and effectiveness values; for the each
illness at primary care, the use of amoxicillin clavulanate is cost saving in order to
complete the treatment successfully.
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OBJECTIVES: HPV vaccination of young girls is a preventive strategy now recom-
mended in most industrialised countries. As HPV can cause cancers and diseases in
both sexes, questions are raised about the health and economic impact of extend-
ing HPV vaccination programme to boys. The aim of this study was to review the
cost-effectiveness studies of boys HPV vaccination and provide recommendations
for future research. METHODS: Cost-effectiveness models of HPV vaccination that
consider boys vaccination as a possible vaccination strategy published before the
end of 2011 were included in the study. Models were compared from a number of
aspects, including modelling approach, model calibration, diseases modelled, HPV
transmission patterns, vaccination and screening strategies and input parameters
(transition probabilities, costs, effectiveness, discount rates). RESULTS: Six US and
three European studies were included in the review. Four in nine used a standard
dynamic model, and three different types of models were used in other studies.
Results differed widely according to HPV-related diseases considered: analyses
modelling cervical cancer only, with or without genital warts, yielded a higher
cost-effectiveness ratio. The comparator considered usually did not account for
vaccination strategies implemented. Results were very sensitive to country-spe-
cific parameters, such as the current vaccination coverage in girls (the most favour-
able cost-effectiveness ratios for boy vaccination were achieved when girls vacci-
nation coverage was low), vaccine price, vaccine characteristics and the
assumption on natural immunity of HPV. CONCLUSIONS: Few analyses examined
the cost-effectiveness of extending HPV vaccination to boys. As methods and pa-
rameters differed across studies, the review provided limited conclusions. The
cost-effectiveness of a girls and boys vaccination programme should include all
benefits expected from HPV vaccination and should be evaluated on a country-by-
country basis to take into account local specificities, such as observed coverage rate
in girls and vaccine price.
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OBJECTIVES: Chronic hepatitis C genotype 1 (HCV) may lead to cirrhosis, liver
cancer, liver transplant, increased mortality. Peginterferon-alpha and ribavirin (PR)
results in complete cure (Sustained Viral Response) in less than 50% of patients.
Aim of this study was to assess the cost-utility of telaprevirPR (TPR) compared to
boceprevirPR (BPR) and PR alone in the management of HCV in adults with mild,
moderate HCV, compensated liver disease, including cirrhosis, who have not been
treated before or have been treated with PR but failed treatment. METHODS: A
Markov model with a lifelong time horizon using annual cycles was developed to
compare TPR, BPR and PR in treatment-naïve patients (TN) and treatment-experi-
enced patients (TE). Clinical data were provided by published phase 3 trials (TPR vs.
PR, BPR vs. PR) and a mixed treatment comparison for the indirect comparison TPR
vs. BPR. Dutch unit costs (direct and indirect) and utilities were taken from a Dutch
observational study in HCV patients. Annual discounting of 4% and 1.5% was ap-
plied on costs and outcomes respectively. The cost per quality-adjusted life-year
(QALY) was calculated from the societal perspective using the Human Capital
Approach. RESULTS: Treating TN with TPR generates 0.85 QALYs gained and €634
additional cost compared to PR, resulting in an incremental cost-utility ratio (ICUR)
of €746/QALY. In TE, TPR dominates PR with cost–savings (-€6,621) and 1.78 addi-
tional QALYs. Also, TPR dominates BPR with higher effects (0.20 in TN; 0.79 in TE)
and cost-savings (-€7,224 in TN; -€22,110 in TE). Sensitivity analysis showed that
time horizon affected the ICERs. The probability to obtain an ICER20,000€/QALY is
100% (probabilistic sensitivity analysis). CONCLUSIONS: Based on the results of
this local adaptation, TPR is highly cost effective versus PR alone in TN patients. It
was a dominant option in all other comparisons (including boceprevir and treat-
ment for TE patients).
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OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C in
Germany (62% genotype 1). Treatment of genotype 1 chronic Hepatitis C has been
improved by recently approved new direct acting antivirals. Clinical studies
showed a significant increase in sustained virological response rates from 38-46%
to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced
triple therapy with Telaprevir (TVRPR) compared to dual therapy (PR) for the
treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated
patients. METHODS: A previously published economic Markov model comparing
triple therapy (TVRPR) and dual therapy (PR) was adjusted for the German health
care context (payer perspective). Effectiveness was measured on the basis of qual-
ity adjusted life years (QALY). Clinical outcomes and drug dosage were taken from
the ADVANCE phase-3 trial. Other model parameters – including utilities - were
adapted from German or if not available from international literature after an
extensive literature search. Drug costs were taken from the German drug directory.
All costs were inflated to the year 2012. A discount rate of 3% and a lifetime horizon
were assumed. RESULTS: Base-case analysis shows that triple treatment (TVRPR)
compared with dual therapy (PR) results in higher costs (€49,378 vs. €30,743) and
better outcomes (16.7 vs. 15.8 QALYs). The incremental costs per QALY gained were
€21,277. Results were robust in multiple sensitivity analyses. Discount rate seemed
to have major impact: a discount rate of 0% results in an ICER of 7,381 €/QALY, a
discount rate of 5% in 34,694 €/QALY. CE acceptability curve shows a probability of
an ICER below 30,000 €/QALY of more than 90%. CONCLUSIONS: Triple therapy
with telaprevir for treatment-naïve HCV-genotype 1 patients is more effective than
dual therapy, but results in higher costs (notably drug costs).
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OBJECTIVES: Herpes Zoster (HZ) is a painful disease resulting from reactivation of
the varicella-zoster virus which can cause post-herpetic neuralgia (PHN), a debili-
tating pain persisting from three months to years after rash onset. The incidence
and severity associated with HZ negatively impacts functional status and quality of
life and increases with advancing age. A vaccine preventing HZ and PHN in people
aged 50 and more will soon be available in Europe. This study aimed to assess the
cost-effectiveness of zoster vaccination in France. METHODS: A published Markov
model was adapted to the French setting. Cost-effectiveness of vaccinating 20% of
individuals aged 70-79 was evaluated over lifetime from a national health care
perspective. Base case analysis considered French epidemiological, economic and
EQ-5D based utility data. The analysis assumed a waning vaccine efficacy of 4.15%
annually as suggested by clinical data. A discount of 4% was applied to costs and
outcomes over the first 30 years and a 2% rate thereafter. Extensive sensitivity
analyses were performed on factors of influence described in the literature.
RESULTS: Incremental cost-effectiveness ratios were estimated at 9,693€ per QALY
gained, 1,529€ per avoided HZ case and 3,480€ per avoided PHN case. The probabil-
ity that the ICERs were below €28,000 to €84,000/QALY (one to three times the GDP
per capita) were greater than 92% and 95%, respectively. Univariate sensitivity
analysis confirmed the favorable cost-effectiveness profile, ranging from 5,793 to
19,565€/QALY gained. Duration of protection and utility estimates were the most
impactful parameters. Vaccination policy targeting other cohorts, such as people
aged 65 years-old was also found cost-effective, with an ICER estimated at 7,217€/
QALY gained. CONCLUSIONS: Beyond epidemiological and clinical evidence,
health-economic evidence supports the implementation of a zoster vaccination
policy in the French senior population aged 70 and over.
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OBJECTIVES: Streptococcus pneumoniaeis a leading cause of life-threatening
pneumococcal disease. In the UK, PPV23 is recommended in the elderly (aged 65
and over) and at-risk adults. In 2007, PCV was introduced in children, leading to a
decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV
serotypes not only in vaccinated children but also in unvaccinated adults. The use
of PCV13 in adults is currently under consideration pending data on efficacy in this
population. This study assessed the CE of PPV23 vs. PCV13 or NoVac in the UK,
accounting for epidemiological changes. METHODS: An existing population-based
Markov model was adapted to the UK. Five health states were considered: no IPD,
IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis sequelae
and death. Epidemiology and costs were estimated from UK sources. The analysis
tracked one cohort of individuals assuming PPV23, PCV13 or NoVac from 2012 until
death. Costs and QALYs were discounted at 3.5%. RESULTS: Over lifetime, vacci-
nating the cohort with PPV23 avoided 226 (vs. PCV13) to 337 (vs. NoVac) IPD cases.
Vaccinating with PPV23 resulted in an increment of 337 (vs. PCV13) to 631 (vs.
NoVac) QALYs. PPV23 was associated with savings of approximately £21 million vs.
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